OBJECTIVE: Stimulant medications are effective treatments for attention-deficit/hyperactivity disorder, but concerns remain about their effects on growth. METHOD: We provide a quantitative analysis of longitudinal studies about deficits in expected growth among children with attention-deficit/hyperactivity disorder treated with stimulant medication. Study selection criteria were use of DSM criteria or clear operational definitions for hyperactivity or minimal brain dysfunction; outcome measures including raw, standardized, or percentile measurement of change in height and/or weight; first assessment of effects on growth occurred during childhood; and follow-up for at least 1 year. For issues not suitable for quantitative analyses, we provide a systematic, qualitative review. RESULTS: The quantitative analyses showed that treatment with stimulant medication led to statistically significant delays in height and weight. This review found statistically significant evidence of attenuation of these deficits over time. The qualitative review suggested that growth deficits may be dose dependent, deficits may not differ between methylphenidate and amphetamine, treatment cessation may lead to normalization of growth, and further research should assess the idea that attention-deficit/hyperactivity disorder itself may be associated with dysregulated growth. CONCLUSIONS: Treatment with stimulants in childhood modestly reduced expected height and weight. Although these effects attenuate over time and some data suggest that ultimate adult growth parameters are not affected, more work is needed to clarify the effects of continuous treatment from childhood to adulthood. Although physicians should monitor height, deficits in height and weight do not appear to be a clinical concern for most children treated with stimulants.
OBJECTIVE: Stimulant medications are effective treatments for attention-deficit/hyperactivity disorder, but concerns remain about their effects on growth. METHOD: We provide a quantitative analysis of longitudinal studies about deficits in expected growth among children with attention-deficit/hyperactivity disorder treated with stimulant medication. Study selection criteria were use of DSM criteria or clear operational definitions for hyperactivity or minimal brain dysfunction; outcome measures including raw, standardized, or percentile measurement of change in height and/or weight; first assessment of effects on growth occurred during childhood; and follow-up for at least 1 year. For issues not suitable for quantitative analyses, we provide a systematic, qualitative review. RESULTS: The quantitative analyses showed that treatment with stimulant medication led to statistically significant delays in height and weight. This review found statistically significant evidence of attenuation of these deficits over time. The qualitative review suggested that growth deficits may be dose dependent, deficits may not differ between methylphenidate and amphetamine, treatment cessation may lead to normalization of growth, and further research should assess the idea that attention-deficit/hyperactivity disorder itself may be associated with dysregulated growth. CONCLUSIONS: Treatment with stimulants in childhood modestly reduced expected height and weight. Although these effects attenuate over time and some data suggest that ultimate adult growth parameters are not affected, more work is needed to clarify the effects of continuous treatment from childhood to adulthood. Although physicians should monitor height, deficits in height and weight do not appear to be a clinical concern for most children treated with stimulants.
Authors: Benjamin M Neale; Sarah Medland; Stephan Ripke; Richard J L Anney; Philip Asherson; Jan Buitelaar; Barbara Franke; Michael Gill; Lindsey Kent; Peter Holmans; Frank Middleton; Anita Thapar; Klaus-Peter Lesch; Stephen V Faraone; Mark Daly; Thuy Trang Nguyen; Helmut Schäfer; Hans-Christoph Steinhausen; Andreas Reif; Tobias J Renner; Marcel Romanos; Jasmin Romanos; Andreas Warnke; Susanne Walitza; Christine Freitag; Jobst Meyer; Haukur Palmason; Aribert Rothenberger; Ziarih Hawi; Joseph Sergeant; Herbert Roeyers; Eric Mick; Joseph Biederman Journal: J Am Acad Child Adolesc Psychiatry Date: 2010-08-05 Impact factor: 8.829
Authors: Laurence L Greenhill; James M Swanson; Lily Hechtman; James Waxmonsky; L Eugene Arnold; Brooke S G Molina; Stephen P Hinshaw; Peter S Jensen; Howard B Abikoff; Timothy Wigal; Annamarie Stehli; Andrea Howard; Michael Hermanussen; Tomasz Hanć Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-08-15 Impact factor: 8.829
Authors: Julie B Penzner; Melissa Dudas; Ema Saito; Vladimir Olshanskiy; Umesh H Parikh; Sandeep Kapoor; Raja Chekuri; Dominick Gadaleta; Jennifer Avedon; Eva M Sheridan; Jane Randell; Anil K Malhotra; John M Kane; Christoph U Correll Journal: J Child Adolesc Psychopharmacol Date: 2009-10 Impact factor: 2.576
Authors: Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow Journal: Pharmacol Biochem Behav Date: 2015-01-29 Impact factor: 3.533